The ABPI is delighted to announce that three new companies have joined their membership organisation which represents the research based pharmaceutical industry in the UK.
Specialist biopharmaceutical company ALK-Abellό has joined as a full member. Devoted to improving the lives of people with allergies, ALK’s focus is on developing innovative treatments that target the cause of allergy. A world leader in allergy vaccination (immunotherapy), ALK prides itself on customer focus, well established leadership and a strong performance culture, with patients at the heart of their work.
Japanese pharmaceutical company Shionogi has joined the ABPI as a full member. Best known for producing antimicrobials and antibiotics, Shionogi’s aim is to deliver medicines that improve quality of life for patients and their families while offering the greatest possible level of satisfaction. To achieve this goal, they are constantly engaged in research, development, manufacturing, and marketing activities.
Innovative diagnostic solutions company Randox has joined the ABPI as a research affiliate. With a focus on making patient diagnosis simpler, faster and more reliable, Randox produces revolutionary products designed to improve clinician’s ability to diagnose quickly and accurately. Furthermore, Randox works with Pharma and research organisations in developing companion diagnostics and cutting edge research and clinical products.
Stephen Whitehead, Chief Executive of the ABPI, welcomed the decisions of ALK-Abellό, Shionogi and Randox to join the ABPI:
"I’m delighted to welcome three new research led companies to the ABPI. The industry is experiencing tremendous change and it is an important time for our members while we strive to improve levels of medicines uptake in the UK and as we engage in pricing negotiations with the Department of Health. The ABPI exists to provide strong leadership and a strong voice for the biopharmaceutical industry and we look forward to supporting our members as they seek to design and deliver innovative new treatments for patients."
For a list of full ABPI members, visit our full membership list.
ABPI Press OfficeTel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811 Email: [email protected]
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.